Genelux (United States)

Genelux (United States)

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Genelux (United States), United States, covering academic research published from 2003 to 2019. Read More.


Open Access Percentage

72%


Total
Publications

123


Total Open
Publications

88


Total
Citations

3.8K


Open Access
Percentage

72%


Total
Publications

123


Total Open
Publications

88


Total
Citations

3.8K

Wikipedia

Website

download

Breakdown

11% 49% 12% 28%

Publisher Open

11%

Both

49%

Other Platform Open

12%

Closed

28%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
20032004200520062007200820092010201120122013201420152016201720182019

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

024681012141618Total Publications
20032004200520062007200820092010201120122013201420152016201720182019

Open

Closed

Publisher Open

54%OA Journal

OA Journal 54%

39

Hybrid 12%

9

No Guarantees 34%

25

Other Platform Open

Domain 96%

72

Institution 40%

30

Public 23%

17

Other Internet 3%

2

Preprint 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
72
Europe PMC
Domain
62
Würzburg University - Online Publication Service of Würzburg University
Institution
26
Semantic Scholar
Public
16
Cold Spring Harbor Laboratory - Cold Spring Harbor Laboratory Institutional Repository
Institution
3
Figshare
Public
2
DOI
Other Internet
2
whiterose.ac.uk OAI-PMH Repository
Institution
1
University of Twente - University of Twente Research Information
Institution
1
University of Granada - Institutional Repository of the University of Granada
Institution
1
1 / 2

Data updated 13 August 2024

Share

Share

Share